A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Study acronym: TeLuRide-008
StatusRecruiting
PhasePhase 2/3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 24 → 28 locations
  2. Study sites: 23 to 24
    • Interventions: EIK1001 (Drug), Nab-paclitaxel + Carboplatin (Drug), Paclitaxel + Carboplatin (Drug), Pembrolizumab (KEYTRUDA®) (Drug), Pemetrexed +… to EIK1001 (Drug), Nab-paclitaxel + Carboplatin (Drug), Paclitaxel + Carboplatin (Drug), Pembrolizumab (KEYTRUDA®) (Drug), Pemetrexed +…
    • Eligibility criteria expanded, about 14 words
    • Collaborators: details revised at 1 of 1 entry
  3. Trial sites expanded: 18 → 23 locationsv6
  4. Trial sites expanded: 14 → 18 locationsv5
  5. Trial sites expanded: 10 → 14 locationsv4
  6. Trial sites expanded: 3 → 10 locations
    • Start date changed from estimate of May 18, 2026 to Jun 15, 2026
    v3
  7. Recruitment opened
    • Trial sites expanded: 0 → 3 locations
    v2
  8. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
Trial Details
NCT Number NCT07365319
Lead Sponsor Eikon Therapeutics
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 750 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov